BNET Industries
Market Cap:$3.7B
Last Fiscal Year Sales:$2.5B
- Public
- US
Dow Jones Description
Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (Medical).
Number of Employees 5,070
Contact Information
311 Bonnie Cir
PO Box 1900
Corona, California 92880
(951) 270-1400
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Watson Pharmaceuticals Q3 net income down
-
Watson Pharmaceuticals names new senior vice president and CFO
-
UPDATE 1-Watson names R. Todd Joyce as new CFO
-
CFOs on the Move: Week Ending Nov. 6
-
Week of Nov. 2, 2009: Eli Lilly Opens Biotech Center; Johnson & Johnson Announces Restructuring;...
-
Watson, Barr settle patent dispute
-
Watson Pharmaceuticals Up 25.3% Since SmarTrend's Buy Recommendation
-
Retrial of Ala.'s drug overpricing lawsuit delayed
-
Watson Pharmaceuticals names G. Frederick Wilkinson as executive VP of global brands
-
Watson Pharmaceuticals, Inc. WPI Names G. Frederick Wilkinson Executive Vice President, Global Brands
-
Former Watson executive returns to co., appointed EVP global brands
News & Analysis
Filter by
watson pharmaceuticals inc. - All News and Analysis
Watson Pharmaceuticals: Income Statement Analysis for the September 2009 Quarter
Seeking Alpha
- 2009-11-08
Neil Carvin submits: Watson Pharmaceuticals, Inc. WPI earned $0.54 per share in the third quarter of 2009, down from $0.60 in the same quarter of last year. [Note: our per-share numbers are slightly different than the official results because we don't adjust for interest expenses on convertible contingent...
Watson Pharmaceuticals Q3 2009 Earnings Call Transcript
Seeking Alpha
- 2009-11-04
Question-and-Answer SessionOperator (Operator's Instructions) Our first question comes from the line of Tim Chiang with FTN Equity. Tim Chiang - FTN Equity Thanks, Paul. Good morning. I wanted to ask you about the metoprolol launch. How has that gone? Did you have significant revenues...
Watson Pharma Look-Ahead to September 2009 Quarterly Results
Seeking Alpha
- 2009-09-23
Neil Carvin submits: The GCFR Overall Gauge of Watson Pharmaceuticals, Inc. (NYSE: WPI) slipped from 43 to 39 of the 100 possible points in the second quarter of 2009. Our income statement and financial gauge analyses explained in some detail how the score was attained....
Watson Pharma Financial Gauge Analysis for June 2009 Quarter
Seeking Alpha
- 2009-08-04
Neil Carvin submits: In an earlier post, we examined Watson Pharmaceuticals' (NYSE: WPI) Income Statement for the June quarter and compared the figures to our "look-ahead" estimates. Second-quarter earnings fell from $0.51 to $0.46 per share, primarily because of the costs to launch the RAPAFLO and Gelnique...
Watson Pharma Income Statement Analysis for June 2009 Quarter
Seeking Alpha
- 2009-07-30
Neil Carvin submits: Watson Pharmaceuticals, Inc. (NYSE: WPI) earned $0.46 per share during the three months that ended on 30 June 2009, down from $0.51 in last year's second quarter. This post examines the Income Statement for the quarter and compares it to our "look-ahead" estimates....
Watson Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript
Seeking Alpha
- 2009-07-29
Watson Pharmaceuticals, Inc. WPI Q2 2009 Earnings Call Transcript July 29, 2009 8:30 am ET
Watson Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript
Seeking Alpha
- 2009-07-29
Question-and-Answer SessionOperator Operator instructions Your first question comes from Randall Stanicky from Goldman Sachs. Bob - Goldman Sachs Hi, good morning guys. This is actually Bob [ph] on for Randall this morning. Paul just quickly on the guidance, I guess could you may be help us understand, what gives...
Watson Pharmaceuticals, Inc. Q1 2009 Earnings Call Transcript
Seeking Alpha
- 2009-05-04
Earnings Call ExcerptWatson Pharmaceuticals, Inc. WPI Q1 2009 Earnings Call April 30, 2009 08:30 am ET Executives Patty Eisenhaur - Executive Director IR Paul Bisaro - President and CEO Mark Durand - CFO David Buchen - General Counsel Analysts Marc Goodman - UBS Greg Gilbert - Banc of America...
Watson Pharmaceuticals, Inc. Q4 2008 Earnings Call Transcript
Seeking Alpha
- 2009-02-19
Question-and-Answer SessionOperator Operator instructions We’ll pause for just a moment to compile the Q&A roster. Your question comes from Greg Gilbert with Bank of America. Paul Bisaro Hey, Greg. Greg Gilbert – Bank of America Hey, thanks. Good morning. Paul, you slipped in a comment about pricing improving, given...
Watson Pharmaceuticals: A Potent Drug Combination
Seeking Alpha
- 2009-01-06
Paul Price submits: Watson WPI develops, manufactures and markets both generic and branded drugs. It also holds a 50% interest in Somerset Pharmaceuticals a joint venture with Mylan Labs MYL. It previously had acquired Andrx Group in November 2006, bringing its stable of marketed products to...
Industry Transcripts by Seeking Alpha
-
Halozyme Therapeutics, Inc. Q3 2009 Earnings Call Transcript
on Nov 06, 2009about HALO
-
Momenta Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript
on Nov 06, 2009about MNTA
-
Emergent BioSolutions Inc. Q3 2009 Earnings Call Transcript
on Nov 05, 2009about EBS
-
Targacept, Inc. Q3 2009 Earnings Call Transcript
on Nov 05, 2009about TRGT
-
Nabi Biopharmaceuticals Q3 2009 Earnings Call Transcript
on Nov 05, 2009about NABI
Glass Door
Watson Pharmaceuticals
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Merck KGaA on Cancer Vaccines: We're Not Crazy, Just Convinced 3 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
